Abstract
A consistently suppressed viral load enables HIV (+) patients to live longer, healthier lives and reduces the probability of transmitting the virus. Since the prevalence of HIV is four times higher among those with psychiatric disorders than in the general population, it is likely that this group would also have greater difficulty remaining in care and achieving viral suppression. A secondary data analysis utilizing screening data from the Preventing AIDS Through Health (PATH) for Triples (PFT) Study were examined to assess HIV load suppression among 254 psychiatric inpatients with comorbid substance use disorders in Philadelphia. Viral load results from the past 12 months were obtained from medical records for 63 inpatients identified as HIV (+). The sample was predominately African American (76%), male (56%), and the average age was 43 years. Psychiatric disorders included depression (64%), schizophrenia (21%), and bipolar disorder (13%) with patients reporting use of alcohol (73%), cocaine (64%), cannabis (29%) and opioids (16%) prior to admission. Among this high risk sample of HIV (+) patients, about one-half (52%) achieved viral suppression, with recent opioid users six times more likely to have a detectable viral load than non-opioid users (OR 6.0; CI 1.1–31.7, p = .035). The 52% viral load suppression rate among psychiatric inpatient was higher than expected, given that the CDC’s national suppression rate among those diagnosed with HIV in the general population is 58%. However, individuals with mental illness and substance use disorders require constant surveillance, monitoring, and supportive services to achieve viral suppression. Many of those who were virally suppressed were engaged in Philadelphia’s extensive treatment network, whereas those who were detectable and enrolled in the PFT intervention were often homeless with unstable psychiatric symptoms and current substance use disorders, particularly opioid abuse.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arnsten, J. H., Demas, P. A., Grant, R. W., Gourevitch, M. N., Farzadegan, H., Howard, A. A., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17, 377–381.
Baker, J. V., Peng, G., Rapkin, J., Abrams, D. I., Silverberg, M. J., MacArthur, R. D., et al. (2008). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS, 22(7), 841–848.
Biradavolu, M., Jia, Y., Withers, K., & Kapetanovic, S. (2016). Factors influencing the delivery of HIV-related services to severely mentally ill individuals: The provider’s perspective. Psychosomatics, 57, 64–70.
Blank, M. B., & Eisenberg, M. M. (2013). Tailored treatment for HIV+ persons with mental illness: The intervention cascade. Journal of Acquired Immune Deficiency Syndromes, 63(01), S44-48.
Blank, M. B., Hanrahan, N. P., Fishbein, M., Wu, E. S., Tennille, J. A., Ten Have, T. R., et al. (2011). A randomized trial of a nursing intervention for HIV disease management among persons with serious mental illness. Psychiatric Services, 62(11), 1318–1324.
Blank, M. B., Hennessy, M., & Eisenberg, M. M. (2014). Increasing quality of life and reducing HIV burden: The PATH+ intervention. AIDS and Behavior, 18(4), 716–725.
Blank, M. B., Himelhoch, S. S., Balaji, A. B., Metzger, D. S., Dixon, L. B., Rose, C. E., et al. (2014). Multisite study of the prevalence of HIV with rapid testing in mental health settings. American Journal of Public Health, 104(12), 2377–2384.
Cairns, G. (2013). Are we underestimating the proportion of virally-suppressed patients in the US? Retrieved from http://www.aidsmap.com/Are-we-underestimating-the-proportion-of-virally-suppressed-patients-in-the-US/page/2600686/.
Center for Disease Control and Prevention. (2015). Vital signs: Demographic and substance use trends among heroin users—United States, 2002–2013. Morbidity and Mortality Weekly Report (MMWR), 64(26), 719–725.
Centers for Disease Control and Prevention. (2017). Understanding the HIV care continuum. Retrieved from https://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf.
Clum, G., Chung, S., Ellen, J. M., & The Adolescent Medicine Trials Network for HIV/AIDS Interventions (2009). Mediators of HIV-related stigma and risk behavior in HIV infected young women. AIDS Care, 21(11), 1455–1462.
Cohen, M., Chen, Y., McCauley, M., Gamble, T., Hosseinipour, M., Kumarasamy, N., et al. (2015). Antiretroviral therapy prevents HIV transmission: Final results of the HPTN 052 randomized controlled trial. Paper presented at the 8th international AIDS Society conference on HIV pathogenesis, treatment and prevention, Vancouver, BC [Abstract MOAC0101LB].
Gardner, E. M., McLees, M. P., Steiner, J. F., Del Rio, C., & Burman, W. J. (2011). The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases, 52, 793–800.
Gossop, M., Stewart, D., Browne, N., & Marsden, J. (2002). Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: Protective effect of coping responses. Addiction, 97, 1259–1267.
Hall, H. I., Frazier, E. L., Rhodes, P., Holtgrave, D. R., Furlow-Parmley, C., Tang, T., et al. (2013a). Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. Journal of the American Medical Association Internal Medicine, 173(14), 1337–1344.
Hall, H. I., Holtgrave, D. R., Tang, T., & Rhodes, P. (2013b). HIV transmission in the United States: Considerations of viral load, risk behavior, and health disparities. AIDS and Behavior, 17(5), 1632–1636.
Himelhoch, S., Brown, C. H., Walkup, J., Chander, G., Korthius, P. T., Afful, J., & Gebo, K. A. (2009). HIV patients with psychiatric disorders are less likely to discontinue HAART.. AIDS, 23(13), 1735–1742.
Horberg, M., Hurley, L., Towner, W., Gambatese, R., Klein, D., & Antoniskis, D. (2013). HIV spectrum of engagement cascade in a large integrated care system by gender-age methodologies. Paper presented at the 20th conference on retroviruses and opportunistic infections (CR01), Atlanta, GA. [Abstract 1033]. Retreived from http://www.retroconference.org/2013b/PDFs/1033.pdf.
Hosmer, D. W., & Lemeshow, S. (2000). Applied logistic regression (2nd ed.). New York: Wiley.
Howe, C. J., Napravnik, S., Cole, S. R., Kaufman, J. S., Adimora, A. A., Elston, B., et al. (2014). African American race and HIV virological suppression: Beyond disparities in clinic attendance. American Journal of Epidemiology, 179(12), 1484–1492.
Hser, Y. I., Evans, E., Huang, D., Brecht, M. L., & Li, L. (2008a). Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. Addictive Behaviors, 33(12), 1581–1589.
Hser, Y. I., Huang, D., Brecht, M. L., Li, L., & Evans, E. (2008b). Contrasting trajectories of heroin, cocaine, and methamphetamine use. Journal of Addictive Diseases, 27(3), 13–21.
Kaaya, S., Eustache, E., Lapidos-Salaiz, I., Musisi, S., Psaros, C., & Wissow, L. (2013). Grand challenges: Improving HIV treatment outcomes by integrating interventions for co-morbid mental illness. PLoS Medicine, 10(5), e1001447. https://doi.org/10.1371/journal.pmed.1001447.
Leserman, J. (2008). Role of depression, stress, and trauma in HIV disease progression. Psychosomatic Medicine, 70(5), 539–545.
Lucas, G. M., Gebo, K. A., Chaisson, R. E., Moore, R. D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban Clinic. AIDS, 16, 767–774.
Mattson, C. L., Freedman, M., Fagan, J. L., Frazier, E. L., Beer, L., Huang, P., et al. (2014). Sexual risk behavior and viral suppression among HIV-infected adults receiving medical care in the United States. AIDS, 28(8), 1203–1211.
Meade, C. S., & Sikkema, K. J. (2005). HIV risk behavior among adults with severe mental illness: A systematic review. Clinical Psychology Review, 25(4), 433–457.
Meyer, J. P., Cepeda, J., Springer, S. A., Wu, J., Trestman, R. L., & Altice, F. L. (2014). HIV in people re-incarcerated in Connecticut prisons and jails: An observational cohort study. Lancet HIV, 1(2), 77–84.
Mugavero, M. J., Lin, H., Allison, J. J., Giordano, T. P., Willig, J. H., Raper, J. L., et al. (2009). Racial disparities in HIV virologic failure: Do missed visits matter? Journal of Acquired Immune Deficiency Syndromes, 50(1), 100–108.
Muthulingam, D., Chin, J., Hsu, L., Scheer, S., & Schwarcz, S. (2013). Disparities in engagement in care and viral suppression among persons with HIV. Journal of Acquired Immune Deficiency Syndromes, 63(1), 112–119.
Naar-King, S., Templin, T., Wright, K., Frey, M., Parsons, J. T., & Lam, P. (2006). Psychosocial factors and medication adherence in HIV-positive youth. AIDS Patient Care and STDs, 20(1), 44–47.
Nanni, M. G., Caruso, R., Mitchell, A. J., Meggiolaro, E., & Grassi, L. (2015). Depression in HIV infected patients: A review. Current Psychiatry Reports, 17(530), 1–11.
National Institutes of Health News. (2015, May 27). Starting antiretroviral treatment early improves outcomes of HIV-infected individuals. Retrieved from http://www.nih.gov/news/health/may2015/niaid-27.htm.
Pence, B. W., Miller, W. C., Gaynes, B. N., & Eron, J. J. (2007). Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 44(2), 159–166.
Pence, B. W., Mills, J. C., Bengtson, A. M., Gaynes, B. N., Breger, T. L., Cook, R. L., et al. (2018). Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. The Journal of the American Medical Association Psychiatry. https://doi.org/10.1001/jamapsychiatry.2017.4726 (Published online February 21, 2018).
Qian, H. Z., Mitchell, V. J., Bebawy, S., Cassell, H., Perez, G., McGowan, C. C., et al. (2014). Current drug use and lack of HIV virologic suppression: Point-of-care urine drug screen versus self-report. BioMedical Center Infectious Diseases, 14, 508. https://doi.org/10.1186/1471-2334-14-508.
Robertson, M., Laraque, F., Mavronicolas, H., Braunstein, S., & Torian, L. (2015). Linkage and retention in care and the time to HIV viral suppression and viral rebound—New York City. AIDS Care, 27(2), 260–267.
Shacham, E., Önen, N. F., Donovan, M. F., Rosenburg, N., & Overton, E. T. (2016). Psychiatric diagnoses among an HIV-infected outpatient clinic population. Journal of the International Association of Providers of AIDS Care, 15(2), 126–130.
Sternhell, P. S., & Corr, M. J. (2002). Psychiatric morbidity and adherence to antiretroviral medication in patients with HIV/AIDS. Australian and New Zealand. Journal of Psychiatry, 36, 528–533.
Walkup, J. T., Sambamoorthi, U., & Crystal, S. (2004). Use of newer antiretroviral treatments among HIV-infected Medicaid beneficiaries with serious mental illness. The Journal of Clinical Psychiatry, 65(9), 1180–1189.
Yehia, B. R., Cui, W., Thompson, W. W., Zack, M. M., McKnight-Eily, L., DiNenno, E., et al. (2014). HIV testing among adults with mental illness in the United States. AIDS Patient Care STDS, 28(12), 628–634.
Acknowledgements
This work was supported by the Penn Center for AIDS Research under Grant P30AI045008; the Penn Mental Health AIDS Research Center under Grant P30MH097488; and the PFT Intervention: Linking Triply-Diagnosed Inpatients to Community Care under Grant R01DA036503.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the instructional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Rights and permissions
About this article
Cite this article
Coviello, D.M., Lovato, R., Apostol, K. et al. Prevalence of HIV Viral Load Suppression Among Psychiatric Inpatients with Comorbid Substance Use Disorders. Community Ment Health J 54, 1146–1153 (2018). https://doi.org/10.1007/s10597-018-0284-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10597-018-0284-2